KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Capital Leases (2016 - 2026)

Biocryst Pharmaceuticals filings provide 11 years of Capital Leases readings, the most recent being $1.4 million for Q4 2025.

  • On a quarterly basis, Capital Leases fell 32.16% to $1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 million, a 32.16% decrease, with the full-year FY2025 number at $1.4 million, down 32.16% from a year prior.
  • Capital Leases hit $1.4 million in Q4 2025 for Biocryst Pharmaceuticals, down from $1.7 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $5.0 million in Q3 2021 to a low of $1.4 million in Q4 2025.
  • Median Capital Leases over the past 5 years was $2.1 million (2024), compared with a mean of $2.6 million.
  • Biggest five-year swings in Capital Leases: soared 60.1% in 2023 and later tumbled 32.16% in 2025.
  • Biocryst Pharmaceuticals' Capital Leases stood at $5.0 million in 2021, then tumbled by 64.71% to $1.8 million in 2022, then soared by 60.1% to $2.8 million in 2023, then fell by 25.34% to $2.1 million in 2024, then crashed by 32.16% to $1.4 million in 2025.
  • The last three reported values for Capital Leases were $1.4 million (Q4 2025), $1.7 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.